Summary for doctors
- High-risk locally advanced disease: pembrolizumab with weekly cisplatin and radiotherapy, then continued [1].
- Recurrent or metastatic disease with PD-L1 CPS 1 or more: pembrolizumab with chemotherapy ± bevacizumab [2].
Dose and schedule
KEYNOTE-A18
High-risk locally advanced cervical cancerEach drug’s schedule in the table
High-risk locally advanced cervical cancer
| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Phase 1 | |||
| Pembrolizumab | 200 mg | IV | Every 3 weeks, 5 doses |
| Cisplatin | 40 mg/m² | IV | Weekly, 5 to 6 doses with radiotherapy |
| Phase 2 | |||
| Pembrolizumab | 400 mg | IV | Every 6 weeks, 15 doses |
Evidence: GOG (1999)
KEYNOTE-826
Recurrent or metastatic cervical cancer, first lineCycle length: Every 21 days
Recurrent or metastatic cervical cancer, first line
| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Pembrolizumab | 200 mg | IV | Day 1 |
| Paclitaxel | 175 mg/m² | IV | Day 1 |
| Cisplatin 50 mg/m² or carboplatin AUC 5 | IV | Day 1 | |
| Bevacizumab (optional) | 15 mg/kg | IV | Day 1 |
Evidence: KEYNOTE (2026), KEYNOTE-826 (2023), KEYNOTE-826 (2021)
Doses follow the trial protocol, guideline or official drug label (source given in the notes of each regimen). Before prescribing, check blood counts, renal and hepatic function, drug interactions and the patient’s condition, and adjust the dose according to the drug label.
Premedication and supportive care
- Paclitaxel premedication; antiemetics based on the platinum.
- Bevacizumab: assess the risk of fistula and bleeding in pelvic disease after radiotherapy.
Monitoring and dose adjustment
- TSH, glucose, liver enzymes and creatinine at baseline and before each cycle; immune-related toxicity as in the immunotherapy toxicity lesson.
- Weekly blood counts and creatinine during chemoradiotherapy.
Main evidence
Show detailsHide
KEYNOTE-A18: 2-year progression-free survival 68% vs 57% [1]. KEYNOTE-826: with CPS 1 or more, 2-year survival 53.0% vs 41.7% [2].
Related cancer types
Treatment regimens (physicians)
Physician tools and lessons
References
4 referencesShow all references, 2 with a study cardClose the reference list
Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.
- 1
- 2
- 3Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer
- 4
This page is based on reputable scientific sources and was last updated on 28 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.
Printed from the website; the full and up-to-date version: https://drdabiri.com/en/regimens/pembrolizumab-cervical-cancer/